Bedeutung der Pneumokokkenimpfung bei Säuglingen und Kleinkindern

Zusammenfassung.

Pneumokokken verursachen schwere und häufige Krankheiten wie Meningitis, Sepsis und Pneumonie bzw. Otitis media und Sinusitis. Die Inzidenz der invasiven Pneumokokken-Infektionen ist am höchsten in den ersten 2 Lebensjahren (Deutschland, 1997 - 1999: 19,5/100 000/Jahr). Jährlich wird in Deutschland mit ca. 220 - 250 Pneumokokken-Meningitiden, mit 50 000 Pneumokokken-Pneumonien in den ersten 5 Lebensjahren und mit über 1 Mio. Erkrankungen an akuter Otitis media im Kindesalter gerechnet. Die Letalität der invasiven Pneumokokken-Erkrankungen ist nach wie vor hoch (1997 - 1999 5,5 %, für die Meningitis sogar 8,3 %). Bleibende Restschäden nach einer Pneumokokken-Meningitis werden bei 20 - 30 % der Kinder registriert. Die Impfung mit der 7-valenten konjugierten Pneumokokken-Vakzine kann bei Kindern in den ersten 2 Lebensjahren ca. 80 % der invasiven Pneumokokken-Erkrankungen sowie 6 % der akuten und 9 - 16 % der rezidivierenden Otitiden verhindern. Wegen des hohen medizinischen und ökonomischen Nutzeffektes sollten alle Kinder in den ersten 2 Lebensjahren immunisiert werden. Diese Forderung scheint auch deshalb gerechtfertigt zu sein, weil aufgrund der hohen Makrolidresistenz in Deutschland und wegen fehlender Zulassung zahlreicher neuer Antibiotika für das Säuglings- oder Kindesalter die Immunprophylaxe für junge Kinder eine wertvolle Alternative darstellt und die 23-valente Vakzine für Kinder in den ersten 2 Lebensjahren nicht eingesetzt werden kann.

Streptococcus pneumoniae is a common cause of meningitis, sepsis, pneumonia, acute otitis media, and sinusitis in children. Children younger than 24 months have the highest rates of invasive pneumococcal infections (Germany 1997 - 1999: 19,5/100 000/year). Pneumococcal infections cause in Germany 220 - 250 cases of meningitis, about 50 000 of pneumonia (children younger than 5 years) and more than 1 million cases of otitis media (children) annually. The case-fatality rate for invasive pneumococcal diseases is high (1997 - 1999 5.5 %, meningitis 8.3 %). 20 - 30 % of survivers from meningitis suffer from CNS-related sequelea. In children up to 2 years vaccination with the heptavalent pneumococcal conjugate vaccine can reduce invasive pneumococcal diseases by about 80 % and otitis media and recurrent otitis media by 6 % and 9 - 16 %, respectively. Due to the increased risk of pneumococcal infections in the first two years of live all children of this age group should be vaccinated. The high rate of resistance of pneumococci against macrolides in Germany, the high rate of non-licensed antibiotics in infants and the inefficacy of the 23-valent vaccine in children younger than 2 years makes the new vaccine to a necessary alternative.

Impfung - Pneumokokken - Meningitis - Pneumonie - Otitis media

Vaccination - pneumococci - meningitis - pneumonia - otitis media

Literatur

• 01 Adam  D, Scholz  H, Helmerking  M. Short-course treatment of 4782 culture-proven cases of group A streptococcal tonsillopharyngitis and incidence of poststreptococcal sequelae.  J Infect Dis. 2000;;  182 509-516
• 02 American Academy of Pediatrics, Committee on Infectious Diseases .Policy statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000; 106: 362-366
• 03 American Academy of Pediatrics, Overturf GD and the Committee on Infectious Diseases .Technical report: Prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics 2000; 106: 367-376
• 04 Black  S, Shinfield  H, Fireman  B, Lewis  E, Ray  P, Hansen  J R, Elvin  L, Ensor  K M, Hackell  J, Siber  G, Malinoski  F, Madore  D, Chang  I, Kohberger  R, Watson  W, Austrian  R, Edwards  K, and the Northern California Kaiser Permanente Vaccine Study Center Group. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children.  Pediatr Infect Dis J. 2000;;  19 187-195
• 05 Boken  D J, Chartrand  S A, Moland  E S, Goering  R V. Colonization with penicillin-nonsusceptible streptococcus pneumoniae in urban and rural child-care centers.  Pediatr Infect Dis J. 1996;;  15 667-672
• 06 Advisory Committee on Immunization Practices (ACIP) .Preventing pneumococcal disease among infants and young children. Morb Mort Month Rep 2000; 49 RR-9: 1-35
• 07 Craig  A S, Erwin  P C, Schaffner  W, Elliott  J A, Moore  W L, Ussery  X T, Patterson  L, Dake  A D, Hannah  S G, Butler  J C. Carriage of multidrug-resistent streptococcus pneumoniae and impact of chemoprophylaxis during an outbreak of meningitis at a day care center.  Clin Infect Dis. 1999;;  29 1257-1264
• 08 Eskola  J. Immunogenicity of pneumococcal conjugate vaccines.  Pediatr Infect Dis J. 2000;;  19 388-393
• 09 Eskola  J, Kilpi  T, Palmu  A, Jokinen  J, Haapakoski  J, Herva  E, Takala  A, Käyhty  H, Karma  P, Kohberger  R, Siber  G, Mäkelä  H for the Finnish Otitis Media Group. Efficacy of a pneumococcal conjugate vaccine against acute otitis media.  New Engl J Med. 2001;;  344 403-409
• 10 Givon-Lavi  N, Dagan  R, Fraser  D, Yagupsky  P, Porat  N. Marked differences in pneumococcal carriage and resistance patterns between day care centers located within a small area.  Clin Infect Dis. 1999;;  29 1274-1280
• 11 Nelson  W L, Kuritzky  J N, Kennedy  D L. Outpatient pediatric antibiotic use in the US: trends and therapy for otitis media, 1977 - 1986. Abstract of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC; 1987:
• 12 Kries  R von, Siedler  A, Schmitt  H J. Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines.  Clin Infect Dis. 2000;;  31 482-487
• 13 Kries  R von, Siedler  A, Schmitt  H J. Epidemiologie von Pneumokokken-Infektionen bei Kindern.  Kinderärtzl Prax. 2000;;  71 435-438
• 14 Levine  O S, Farley  M, Harrison  L H, Lefkowitz  L, MyGeer  A, Schwartz  B. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America.  Pediatrics. 1999;;  103 1-5
• 15 Reinert  R R, Simic  S, Laham  A, Reinert  S, Lemperle  M, Lütticken  R. Antimicrobial resistence of streptococcus pneumoniae recovered from outpatients with respiratory tract infections in Germany, 1998 - 1999: Results of a national surveillance study.  J Clin Microbiol. 2001;;  39 (in press)
• 16 Robert Koch Institut .Teil 4: Infektionen des Zentralnervensystems - 2. Folge. Andere bakterielle Meningitiden. Epidemiol Bull 2000; Nr. 36: 287-289
• 17 Takala  A K, Gero  J, Kela  E, Ronnberg  P R, Koskenniemi  E, Eskola  J. Risk factors for primary invasive pneumococcal disease among children in Finland.  JAMA. 1995;;  273 859-864
• 18 Yagupsky  P, Porat  N, Fraser  D, Prajgrod  F, Merires  M, McGee  L, Klugman  K P, Dagan  R. Acqusition, carriage, and transmission of pneumococci with decreased antibiotic susceptibility in young children attending a day care facility in southern Israel.  J Infect Dis. 1998;;  177 1003-1012